CADL Sale Disclosure
Tak Paul Peter · SEC Form 4 · Filed Sep 11, 2026
Sale
Calculated transaction value
$2.54M
Tak Paul Peter Chief Executive Officer
CADL
Candel Therapeutics
CADL
Transaction date
Sep 10, 2026
Public filing date
Sep 11, 2026
Filing lag
Filed 1 day later
CADL daily price context
Close on/before transaction
$11.33
Sep 10, 2026
Close before public filing
$11.33
Sep 10, 2026
Return since public filing
-8.21%
Through Sep 11, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 220,866 shares @ $11.5
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001873905-26-000002
Filing cohort
Transactions in this filing
Showing 4 of 4
Trades
4
Issuers
1
Estimated value
$3.35M
Buys / sales
0 / 2
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Candel Therapeutics, Inc. CADL | Sale | Sep 11, 2026 | $620.89K |
| Candel Therapeutics, Inc. CADL | Exercise | Sep 10, 2026 | $193.75K |
| Candel Therapeutics, Inc. CADL Current | Sale | Sep 10, 2026 | $2.54M |
| Candel Therapeutics, Inc. CADL | Exercise | Sep 10, 2026 | $0 |